S100B and NSE as useful postmortem biochemical markers of traumatic brain injury in autopsy cases

Journal of Neurotrauma

Volumn 30, Issue 22, 2013, Pages 1862-1871

  Ondruschka, Benjamin ^a   Pohlers, Dirk ^b   Sommer, Gerald ^c   Schober, Kristin ^a,d   Teupser, Daniel ^e,f   Franke, Heike ^a   Dressler, Jan ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c Innovation Center Computer Assisted Surgery   (Germany)

^d German Air Force Institute of Aviation Medicine   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

NSE; postmortem biochemistry; S100B; survival time; traumatic brain injury

Indexed keywords

NEURON SPECIFIC ENOLASE; PROTEIN S100B;

ADULT; ARTICLE; AUTOPSY; CAUSE OF DEATH; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; POSTMORTEM CHANGE; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SURVIVAL TIME; TRAUMATIC BRAIN INJURY;

ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; BIOLOGICAL MARKERS; BRAIN INJURIES; CAUSE OF DEATH; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 84887078789     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2013.2895     Document Type: Article

References (82)

1. Asemota, A.O., George, B.P., Bowman, S.M., Haider, A.H. and Schneider, E.B. (2013). Causes and trends in traumatic brain injury for United States adolescents. J. Neurotrauma 30, 67-75.
2. Cubbin, C., LeClere, F.B. and Smith, G.S. (2000). Socioeconomic status and injury mortality: Individual and neighborhood determinants. J. Epidemiol. Community Health 54, 517-524.
3. Hausmann, R., Biermann, T., Wiest, I., Tübel, J. and Betz, P. (2004). Neuronal apoptosis following human brain injury. Int. J. Legal Med. 118, 32-36.
4. Hausmann, R. and Betz, P. (2000). The time course of the vascular response to human brain injury: an immunohistochemical study. Int. J. Legal Med. 113, 288-292.
5. Nogami, M., Takatsu, A., Endo, N. and Ishiyama, I. (1999). IgG immunohistochemistry for the assessment of brain injuries in forensic autopsies. Legal Med. 1, 76-79.
6. Oehmichen, M., Meissner, C., von Wurmb-Schwark, N. and Schwark, T. (2003). Methodical approach to brain hypoxia/ischemia as a fundamental problem in forensic neuropathology. Legal Med. 5, 190-201.
7. Palmiere, C. and Mangin, P. (2012). Postmortem chemistry update part I. Int. J. Legal Med. 126, 187-198.
8. Palmiere, C. and Mangin, P. (2012). Postmortem chemistry update part II. Int. J. Legal Med. 126, 199-215.
9. Coe, J.I. (1993). Postmorten chemistry update. Emphasis on forensic application. Am. J. Forensic Med. Pathol. 14, 91-117.
10. Maeda, H., Zhu, B.L., Ishikawa, T., Quan, L. and Michiue, T. (2009). Significance of postmortem biochemistry in determining the cause of death. Legal Med. 11, S46-S49.
11. Osuna, E., Perez-Carceles, M.D., Luna, A. and Pounder, D.J. (1992). Efficacy of cerebro-spinal fluid biochemistry in the diagnosis of brain insult. For. Sci. Int. 52, 193-198.
12. Donato, R. (2001). S100: A multigenetic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33, 637-668.
13. Sen, J. and Belli, A. (2007). S100B in neuropathologic states: the CRP of the brain? J. Neurosci. Res. 15, 1373-1380.
14. Steiner, J., Bielau, H., Bernstein, H.G., Bogerts, B. and Wunderlich, M.T. (2006). Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 77, 1284-1287.
15. Petzold, A., Jenkins, R., Watt, H.C., Green, A.J., Thompson, E.J., Keir, G., Fox, N.C. and Rossor, M.N. (2003). Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci. Lett. 336, 167-170.
16. Kleindienst, A., Hesse, F., Bullock, M.R. and Buchfelder, M. (2007). The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog. Brain Res. 161, 317-325.
17. Janeczko, K. (1991). The proliferative response of S-100 proteinpositive glial cells to injury in the neonatal rat brain. Brain Res. 565, 86-90.
18. Schiavi, P., Iaccarino, C. and Servadei, F. (2012). The value of the calcium binding protein S100 in the management of patients with traumatic brain injury. Acta Biomed. 83, 5-20.
19. Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R.R., Weber, D.J. and Carrier, F. (2001). Inhibition of p53 transcriptional activity by the S100B calcium binding protein. J. Biol. Chem. 276, 35037-35041.
20. Herrmann , M., Vos, P., Wunderlich, M.T., de Bruijn, C.H. and Lamers, K.J. (2000). Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31, 2670-2677.
21. Romero-Aleman Mdel, M., Monzo-Mayor, M., Yanes, C., Arbelo-Galvan, J.F., Lang, D., Renau-Piqueras, J. and Negrin-Martinez, C. (2003). S100 immunoreactive glial cells in the forebrain and midbrain of the lizard gallotia galloti during ontogeny. J. Neurobiol. 57, 54-66.
22. Baydas, G., Reiter, R.J., Yasar, A., Tuzcu, M., Akdemir, I. and Nedzvetskii, V.S. (2003). Melationin reduces glial reactivity in the hippocampus, cortex and cerebellum of streptozotocin-induced diabetic rats. Free Radic. Biol. Med. 35, 797-804.
23. Steiner, J., Bernstein, H.G., Bielau, H., Berndt, A., Brisch, R., Mawrin, C., Keilhoff, G. and Bogerts, B. (2007). Evidence for a wide extraastrocytic distribution of S100B in human brain. BMC Neurosci. 8, 2.
24. Kligman, D. and Marshak, D.R. (1985). Purification and characterization of a neurite extension factor from bovine brain. Proc. Natl. Acad. Sci. U.S.A. 82, 7136-7139.
25. Barger, S.W., Van Eldick, L.J. and Mattson, M.P. (1995). S100 beta protects hippocampal neurons from damage induced by glucose deprivation. Brain Res. 677, 167-170.
26. Sorci, G., Riuzzi, F., Agneletti, A.L., Marchetti, C. and Donato, R. (2004). S100B causes apoptosis in a myoblast cell line in a RAGEindependent manner. J. Cell Physiol. 199, 274-283.
27. Selinfreund, R.H., Barger, S.W., Pledger, W.J. and Van Eldik, L.J. (1991). Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 88, 3554-3448.
28. Lamers, K.J.B, Vos, P., Verbeek, M.M., Rosmalen, F., van Geel, W.J.A and van Engelen, B.G.M. (2003). Protein S-100B, neuronspecific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 61, 261-264.
29. Barger, S.W. and van Eldik, L.J. (1992). S100 beta stimulates calcium fluxes in glial and neuronal cells. J. Biol. Chem. 267, 9689-9694.
30. Barzo, P., Marmarou, A., Fatouros, P., Corwin, F. and Dunbar, J. (1996). Magnetic resonance imaging-monitored acute blood-brain barrier changes in experimental traumatic brain injury. J. Neurosurg. 85, 1113-1121.
31. Vos, P.E., Lamers, K.J., Hendriks, J.C., van Haaren, M., Beems, T., Zimmermann, C., van Geel, W., de Reus, H., Biert, J. and Verbeek, M.M. (2004). Glial and neuronal protein in serum predict outcome after severe traumatic brain injury. Neurology 62, 1303-1310.
32. Berger, R.P., Pierce, M.C., Wisniewski, S.R., Adelson, P.D. and Kochanek, P.M. (2002). Serum S100B concentrations are increased after closed head injury in children: a preliminary study. J. Neurotrauma 19, 1405-1409.
33. Raabe, A., Grolms, C. and Seifert, V. (1999). Serum markers of brain damage and outcome prediction in patients after severe head injury. Br. J. Neurosurg. 13, 56-59.
34. Schiavi, P., Iaccarino, C. and Servadei, F. (2012). The value of the calcium binding protein S100 in the management of patients with traumatic brain injury. Acta Biomed. 83, 5-20.
35. Wojtczak-Soska, K. and Lelonek, M. (2010). S-100B protein: an early prognostic marker after cardiac arrest. Cardiol. J. 17, 532-536.
36. Routsi, C., Stammataki, E., Nanas, S., Psachoulia, C., Stathopoulos, A., Koroneos, A., Zervou, M., Jullien, G. and Roussos, C. (2006). Increased levels of serum S100B protein in critically ill patients without brain injury. Shock 26, 20-24.
37. Marangos, P.J. and Schmechel, D.E. (1987). Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 10, 269-295.
38. Cooper, E.H. and Splinter, T.A.W. (1987). Neuron-specific enolase (NSE): a useful marker in small cell lung cancer. Lung Cancer 3, 61-66.
39. Haimoto, H., Takahashi, Y., Koshikawa, T., Nagura, H. and Kato K. (1985). Immunohisto-chemical localisation of c-enolase in normal human tissues other than nervous and neuroendocrine tissues, Lab. Invest. 52, 257-263.
40. Schmechel, D., Marangos, P.J. and Brightmann, M. (1978). Neuronespecific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 276, 834-836.
41. Murray, G.I., Duncan, M.E., Melvin, W.T. and Fothergill, J.E. (1993). Immunhistochemistry of neurone specific enolase with gamma subunit specific anti-peptide monoclonal antibodies. J. Clin. Pathol. 46, 993-996.
42. Ogata, M. and Tsuganezawa, O. (1999). Neuron-specific enolase as an effective immunohistochemical marker for injured axons after fatal brain injury. Int. J. Legal Med. 113, 19-25.
43. Steinberg, R., Scarna, H., Keller, A. and Pujol, J.F. (1983). Release of neuron specific enolase (NSE) in cerebrospinal fluid following experimental lesions of the rat brain. Neurochem. Int. 5, 145-151.
44. Bandyopadhyay, S., Hennes, H., Gorelick, M.H., Wells, R.G. and Walsh-Kelly, C.M. (2005). Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. Acad. Emerg. Med. 12, 732-738.
45. Persson, L., Ha°rdemark, H.G., Gustafsson, J., Rundström, G., Melde-Hartvig, I., Esscher, T. and Pa°hlman, S. (1987). S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18, 911-918.
46. Pelinka, L.E., Hertz, H., Mauritz, W., Harada, N., Jafarmadar, M., Albrecht, M., Redl, H. and Bahrami, S. (2005). Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 24, 119-123.
47. Zurek, J. and Fedora, M. (2012) The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir. (Wien) 154, 93-103.
48. Mercier, E., Boutin, A., Lauzier, F., Gergusson, D.A., Simard, J.F., Zarychanski, R., Moore, L., McIntyre, L.A., Archambault, P., Lamontagne, F., Légaré, F., Randall, E., Nadeau, L., Rousseau, F. and Turgeon, A.F. (2013). Predictive value of S-100b protein for prognosis in patients with moderate and seere traumatic brain injury: systematic review and meta-analysis. B.M.J. 346, doi: 10.1136/bmj.f1757.
49. Calcagnile, O., Undén, L. and Undén, J. (2012). Clinical validation of S100B use in management of mild head injury. B.M.C. Emerg. Med. 13, doi: 10.1186/1471-227X-12-13.
50. Kleine, T.O., Benes, L. and Zö fel, P. (2003). Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res. Bull. 61, 265-279.
51. Hanrieder, J., Wetterhall, M., Enblad, P., Hillered, L. and Bergquist, J. (2009). Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates. J. Neurosci. Methods 177, 469-478.
52. Staffa, K., Ondruschka, B., Franke, H. and Dreßler, J. (2012). Cerebellar gene expression following human traumatic brain injury. J. Neurotrauma 29, 2716-2721.
53. Dressler, J., Hanisch, U., Kuhlisch, E. and Geiger, K. D. (2007). Neuronal and glial apoptosis in human traumatic brain injury. Int. J. Legal Med. 121, 365-375.
54. Wyler, D., Marty, W. and Bär, W. (1994). Correlation between the post-mortem cell content of cerebrospinal fluid and time of death. Int. J. Legal Med. 106, 194-199.
55. Vásquez, M.D., Sánchez-Rodriguez, F., Osuna, E., Diaz, J., Cox, D.E., Pérez-Cárceles, M.D., Martinez, P., Luna, A. and Pounder, D.J. (1995). Creatine kinase BB and neuron-specific enolase in cerebrospinal fluid in the diagnosis of brain insult. Am. J. Forensic Med. Pathol. 16, 210-214.
56. Raabe, A., Kopetsch, O., Gross, U., Zimmermann, M. and Gebhart, P. (2003). Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin. Chem. Lab. Med. 41, 700-703.
57. Beaudeux, J., Léger, P., Dequen, L., Gandjbakhch, I., Criat, P. and Foglietti, M.J. (2000). Influence of hemolysis on the measurement of S-100beta protein and neuron-specific enolase plasma concentrations during coronary artery bypass grafting. Clin. Chem. 46, 989-990.
58. Gao, F., Harris, D.N. and Sapsed-Byrne, S. (1997). Neuron-specific Enolase and Sangtec 100 assays during cardiac surgery: part III. Does haemolysis affect their accuracy? Perfusion 12, 171-177.
59. Portela, L.V., Tort, A.B., Schaf, D.V., Ribeiro, L., Nora, D.B., Walz, R., Rotta, L.N., Silva, C.T., Busnello, J.V., Kapczinski, F., Goncalves, C.A. and Souza, D.O. (2002). The serum S100B concentration is age dependent. Clin. Chem. 48, 950-952.
60. Wiesmann, M., Missler, U., Gottmann, D. and Gehring, S. (1998). Plasma S-100b protein concentration in healthy adults is age-and sexindependent. Clin. Chem. 44, 1056-1058.
61. Li, D.R., Zhu, B.L., Ishikawa, T., Zhao, D., Michiue, T. and Maeda, H. (2006). Postmortem serum protein S100B levels with regard to the cause of death involving brain damage in medicolegal autopsy cases. Legal Med. 8, 71-77.
62. Ramont, L., Thoannes, H., Volondat, A., Chstang, F., Millet, M.C. and Maquart, F.X. (2005). Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin. Chem. Lab. Med. 43, 1215-1217.
63. Casmiro, M., Maitan, S., De Pasquale, F., Cova, V., Scarpa, E. and Vignatelli, L. (2005). Cerebrospinal fluid and serum neuron-specific enolase concentrations in a normal population. Eur. J. Neurol. 12, 369-374.
64. Dimopoulou, I., Korfias, S., Dafni, U., Anthi, A., Psachoulia, C., Jullien, G., Sakas, D.E. and Roussos, C. (2003). Protein S-100b serum levels in trauma-induced brain-death. Neurology 60, 947-951.
65. Maeda, H., Ishikawa, T. and Michiue, T. (2011). Forensic biochemistry for functional investigation of death: Concept and practical application. Legal Med. 13, 55-67.
66. Li, D.R., Michiue, T., Zhu, B.L., Ishikawa, T., Quan, L., Zhao, D., Yoshida, C., Chen, J.H., Wang, Q., Komatsu, A., Azuma, Y. and Maeda, H. (2009). Evaluation of postmortem S100B levels in the cerebrospinal fluid with regard to the cause of death in medicolegal autopsy. Legal Med. 11, S273-S275.
67. Eng, L. and Ghirnikar, R. (1994). GFAP and astrogliosis. Brain Pathol. 4, 229-237.
68. Li, D.R., Zhu, B.L., Ishikawa, T., Zhao, D., Michiue, T. and Maeda, H. (2006). Immunhistochemical distribution of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy. Legal Med. 8, 78-85.
69. Pelinka, L.E., Kroepfl, A., Leixnering, M., Buchinger, W., Raabe, A. and Redl, H. (2004). GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma 21, 1553-1561.
70. Savola, O., Pythinen, J., Leino, T.K., Siitonen, S., Niemela, O. and Hillborn, M. (2004). Effects of head and extracranial injuries on serum protein S100B level in trauma patients. J. Trauma 56, 1229-1234.
71. Undén, J. and Romner, B. (2010). Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: An evidence-based review and meta-analysis. J. Head Trauma Rehabil. 25, 228-240.
72. Ohrt-Nissen, S., Friis-Hansen, L., Dahl, B., Stensballe, J., Romner, B. and Rasmussen, L.S. (2011). How does extracerebral trauma affect the clinical value of S100B measurements? Emerg. Med. J. 28, 941-944.
73. Suzuki, F., Kato, K. and Nakajima, T. (1983). Enhancement of adipose S-100 protein release by catecholamines. J. Biochem. 94, 1707-1710.
74. Ingebrigtsen, T. and Romner, B. (2002). Biochemical serum markers of traumatic brain injury. J. Trauma 52, 798-808.
75. Jackson, R.G., Samra, G.S., Radcliffe, J., Clark, G.H. and Prive, C.P. (2000). The early fall in levels of S-100 beta in traumatic brain injury. Clin. Chem. Lab. Med. 38, 1165-1167.
76. Pleines, U.E., Morganti-Kossmann, M.C., Rancan, M., Joller, H., Trentz, O. and Kossmann, T. (2001). S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J. Neurotrauma 18, 491-498.
77. Raabe, A., Kopetsch, O., Woszczyk, A., Lang, J., Gerlach, R., Zimmermann, M. and Seifert, V. (2003). Serum S100B protein as a molecular marker in severe traumatic brain injury. Restor. Neurol. Neurosci. 21, 159-169.
78. Vos, P.E., Jacobs, B., Andriessen, T.M.J.C., Lamers, K.J.B., Borm, G.F., Beems, T., Edwards, M., Rosmalen, C.F. and Vissers, J.L.M. (2010). GFAP and S100B are biomarkers of traumatic brain injury. An observational cohort study. Neurology 75, 1786-1793.
79. Oertel, M., Schumacher, U., McArthur, D.L., Kästner, S. and Böker, D.K. (2006). S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J. Clin. Neurosci. 13, 834-840.
80. Bellander, B.M., Olafsson, I.H., Ghatan, P.H., Bro Skejo, H.P., Hansson, L.O., Wanecek, M. and Svensson, M.A. (2010). Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir. (Wien) 153, 90-100.
81. Reali, C., Scintu, F., Pillai, R., Donato, R., Michetti, F. and Sogos, V. (2005) S100b counteracts effects of the neurotoxicant trimethyltin on astrocytes and microglia. J. Neurosci. Res. 81, 677-686.
82. Goodman, J.C., Valadka, A.B., Gopinath, S.P., Cormio, M. and Robertson, C.S. (1996). Lactate and excitatory amino acids measured by microdialysis are decreased by pentobarbital coma in head-injured patients. J. Neurotrauma 13, 549-556.